AlphaGenix is a life science company that develops novel products and technologies for basic and clinical research with a particular emphasis on stem cell biology, biomaterials and regenerative medicine. In addition, the company conducts regenerative medicine research that involves basic science and translational preclinical research using stem cell regulatory network discoveries and novel preclinical studies utilizing animal models.
The company is engineering human extracellular matrix （ECM） proteins for clinical applications. These natural biomaterials play a role in treating a wide array of diseases including, but not limited to, neurological disorders and hereditary muscle diseases. Currently these products are in preclinical development with the intent of entering clinical trials within the next 24 months.
AlphaGenix's human ECM, AlphaMax, is being used as a scaffold for tissue engineering, reconstruction and repair. In addition, it has shown efficacy in a xenograft tumor model in reducing tumor formation in conjunction with stem cells. It was determined that AlphaMax was able to cause a significant reduction in tumor size due to its ability to augment delivery of the stem cells to the tumor site and facilitated tumor killing by the therapeutic stem cells.
The company is also investigating the use of cell therapy for the treatment of traumatic brain injury （TBI）. In a rat model of TBI, stem cell therapy after moderate TBI improves motor and cognitive function. The placement and method of delivery are important factors in cell survival and may improve cell survival and cognitive recovery.
AlphaGenix has its laboratories and corporate offices at the Purdue Research Park in West Lafayette, IN and has research collaborations with Purdue University. The laboratories include a state-of-the-art molecular and cell biology facility and advanced scientific imaging equipment.